Development code · Small Molecule
NBI-'568
NBI-'568 is a development code for Direclidine (NBI-1117568), developed by Neurocrine Biosciences, Inc..
- Status
- Phase 3 for Schizophrenia
- Mechanism
- M4 Agonist
- Developer
- Neurocrine Biosciences, Inc.
Programs
- Direclidine (NBI-1117568) for SchizophreniaPhase 3Active
- Direclidine (NBI-1117568) for Bipolar disorderPhase 2Recruiting
Also known as
- NBI-1117568
- HTL-0016878
- HTL0016878
- direclidine
- 1803346-98-6
- ethyl (2R,4S)-2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate